PolitMaster.com is a comprehensive online platform providing insightful coverage of the political arena: International Relations, Domestic Policies, Economic Developments, Electoral Processes, and Legislative Updates. With expert analysis, live updates, and in-depth features, we bring you closer to the heart of politics. Exclusive interviews, up-to-date photos, and video content, alongside breaking news, keep you informed around the clock. Stay engaged with the world of politics 24/7.


  • Owner: SNOWLAND s.r.o.
  • Registration certificate 06691200
  • 16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
  • Czech Republic

Supreme Court Ruling Could Put the F.D.A. in the Cross Hairs of Its Critics

The Food and Drug Administration, which oversees a vast swath of items people use every day, is expected to see an increase — perhaps an onslaught — of lawsuits following the Supreme Court’s decision on Friday.

“This is disastrous for public health. This is disastrous for the critical role of science-based regulatory agencies,” said Mitch Zeller, a former F.D.A. associate commissioner and tobacco division director. “Chevron has worked well for half a century and makes a lot of sense.”

Challenges could range from whether tainted spinach can be traced back to a farm to the very core of the F.D.A.’s decisions on whether drugs are safe and effective enough to be sold in the United States.

“F.D.A. has always been called the gold standard for product approval throughout the world,” said Perham Gorji, a partner at the law firm DLA Piper and former deputy chief counsel at the F.D.A. “Less deference to F.D.A. is going to obviously change what’s available in terms of products that are available here in the United States.”

The agency employs about 18,000 people, many of whom are doctors or have advanced degrees in biostatistics, chemistry and toxicology. Given the complexity of some scientific decisions the agency makes, attorneys who focus on the F.D.A. said initial challenges might focus on areas in which the F.D.A. exerts policy clout, including some that touch on drug pricing.

Chad Landmon, an attorney with Axinn who leads the F.D.A. practice group, predicted that early lawsuits could stem from a mix of problems companies face.

“I think companies are going to be much more aggressive and generally are going to be looking for opportunities to challenge the F.D.A.,” Mr. Landmon said.

Others expect a broad onslaught from tobacco companies

Read more on nytimes.com